<DOC>
	<DOC>NCT00097526</DOC>
	<brief_summary>This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.</brief_summary>
	<brief_title>Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan Previous enrollment in the NCGS core study, 85036 Tanner Stage 4 or greater Either spontaneous or induced puberty Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height Current therapy with a non Genentech GH product Pregnancy (to avoid exposure to low levels of radiation from DXA scanners) Bilateral hip replacement Weight &gt;130 kg (286 lb.)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Growth Hormone Deficiency</keyword>
</DOC>